Enhancing Success in Panic
Disorder Clinical Trials: From FDA
Approvals to Improved Protocols

Panic Disorder represents a significant and complex subset of anxiety disorders, characterized by recurrent and unexpected panic attacks that can severely disrupt daily life.

This whitepaper delves into the evolving understanding, prevalence, and treatment approaches for Panic Disorder, underpinned by a synthesis of the latest research and clinical insights. It explores the biological, psychological, and environmental factors contributing to the disorder, highlighting the challenges in its diagnosis and management.

With approximately 2.7% of U.S. adults affected annually and a notable global prevalence, this condition demands attention from healthcare providers, researchers, and policy makers. The report examines the advancements in therapeutic interventions, from first-line pharmacological options to evidence-based psychotherapies, as well as emerging clinical trials and market trends in treatment options. It also identifies the pivotal endpoints and challenges that continue to shape research and regulatory strategies in this field.

At iNGENū, we are dedicated to advancing the understanding and treatment of Panic Disorder. Through cutting-edge research and a patient-centered approach, our mission is to deliver innovative solutions that improve the lives of individuals and families impacted by this challenging condition.